Biotech Values

[genisi]

They've also got another new product called Stelara, an interleukin-12 and -23 inhibitor used to treat psoriasis. That's on track to become a billion-dollar product by 2012. [I question this sales projection.]

There's a recent meta-analysis that did not find a stat-sign difference in major CV AE in patients with chronic plaque psoriasis treated with anti-interleukin (IL)-12/23 drugs (or anti-TNF-a) compared with placebo. However, I doubt this study will accelerate the use of Stelara as the authors raised limitation issues with the analysis saying it may not have been powered to detect a significant increase in SE.

http://www.ncbi.nlm.nih.gov/pubmed/21862748